Actinium Pharmaceuticals, Inc.

NYSE American ATNM

Actinium Pharmaceuticals, Inc. EBITDA for the Trailing 12 Months (TTM) ending September 30, 2024: USD -44.15 M

Actinium Pharmaceuticals, Inc. EBITDA is USD -44.15 M for the Trailing 12 Months (TTM) ending September 30, 2024, a 15.28% change year over year. EBITDA means earnings before interest, taxes, depreciation, and amortization, which measures a company's operating performance by excluding non-operating expenses.
  • Actinium Pharmaceuticals, Inc. EBITDA for the Trailing 12 Months (TTM) ending September 30, 2023 was USD -52.12 M, a -72.65% change year over year.
  • Actinium Pharmaceuticals, Inc. EBITDA for the Trailing 12 Months (TTM) ending September 30, 2022 was USD -30.19 M, a -32.14% change year over year.
  • Actinium Pharmaceuticals, Inc. EBITDA for the Trailing 12 Months (TTM) ending September 30, 2021 was USD -22.84 M, a -13.31% change year over year.
  • Actinium Pharmaceuticals, Inc. EBITDA for the Trailing 12 Months (TTM) ending September 30, 2020 was USD -20.16 M, a 14.11% change year over year.
Key data
Date EBITDA Net Income EPS (Diluted) Shares (Diluted, Weighted)
Market news
Loading...
NYSE American: ATNM

Actinium Pharmaceuticals, Inc.

CEO Mr. Sandesh C. Seth M.B.A., M.S.
IPO Date Dec. 27, 2012
Location United States
Headquarters 275 Madison Avenue
Employees 49
Sector Health Care
Industries
Description

Actinium Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for bone marrow transplant (BMT) or a type of cellular therapy, and for other adoptive cell therapies. Its lead product candidate, I-131 apamistamab (Iomab-B) that is in a pivotal Phase III clinical trial for elderly relapsed or refractory acute myeloid leukemia trial for BMT conditioning; and a Phase I study with a CD19- targeted CAR T-cell therapy with memorial sloan kettering cancer center. The company also offers clinical and preclinical development programs that utilize multiple isotopes, including Actinium-225, Iodine-131, and Lutetium-177 directed at multiple validated cancer targets, including CD45, CD33, CD38, CD47, HER2, and HER3 for targeted conditioning prior to cell and gene therapies, such as bone marrow transplant and cancer therapeutics as single agents or in combination with other therapeutic modalities. It has collaboration with Astellas Pharma, Inc. to develop theranostics for solid tumor indications; EpicentRx, Inc that focuses on a novel CD47 immunotherapy targeted radiotherapy; and AVEO Oncology that focuses on developing a HER3 targeting ARC for solid tumors. The company was incorporated in 2000 and is based in New York, New York.

Similar companies

KOD

Kodiak Sciences Inc.

USD 7.60

-2.69%

RVPH

Reviva Pharmaceuticals Holdings, Inc.

USD 1.58

-17.28%

RNAZ

TransCode Therapeutics, Inc.

USD 3.36

5.66%

VKTX

Viking Therapeutics, Inc.

USD 33.93

-12.73%

MDGL

Madrigal Pharmaceuticals, Inc.

USD 274.12

-9.74%

FBIO

Fortress Biotech, Inc.

USD 1.90

-3.55%

AXSM

Axsome Therapeutics, Inc.

USD 84.60

-5.23%

TGTX

TG Therapeutics, Inc.

USD 29.74

7.48%

ANVS

Annovis Bio, Inc.

USD 4.67

-2.10%

RIGL

Rigel Pharmaceuticals, Inc.

USD 16.69

-2.46%

SGMO

Sangamo Therapeutics, Inc.

USD 1.02

-5.56%

EXEL

Exelixis, Inc.

USD 35.65

0.99%

SAVA

Cassava Sciences, Inc.

USD 2.61

-4.40%

AFMD

Affimed N.V.

USD 1.07

-4.46%

StockViz Staff

January 15, 2025

Any question? Send us an email